Easton Capital Expenditures vs Change To Netincome Analysis

EAPH Stock

USD 0.0001 0.00 0.00%

Easton Pharmaceutica financial indicator trend analysis is much more than just examining Easton Pharmaceutica latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Easton Pharmaceutica is a good investment. Please check the relationship between Easton Pharmaceutica Capital Expenditures and its Change To Netincome accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Easton Pharmaceutica. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in Easton Stock please use our How to Invest in Easton Pharmaceutica guide.

Capital Expenditures vs Change To Netincome

Capital Expenditures vs Change To Netincome Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Easton Pharmaceutica Capital Expenditures account and Change To Netincome. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Easton Pharmaceutica's Capital Expenditures and Change To Netincome is 0.54. Overlapping area represents the amount of variation of Capital Expenditures that can explain the historical movement of Change To Netincome in the same time period over historical financial statements of Easton Pharmaceutica, assuming nothing else is changed. The correlation between historical values of Easton Pharmaceutica's Capital Expenditures and Change To Netincome is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Expenditures of Easton Pharmaceutica are associated (or correlated) with its Change To Netincome. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Change To Netincome has no effect on the direction of Capital Expenditures i.e., Easton Pharmaceutica's Capital Expenditures and Change To Netincome go up and down completely randomly.

Correlation Coefficient

0.54

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Capital Expenditures

Capital Expenditures are funds used by Easton Pharmaceutica to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Easton Pharmaceutica operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Change To Netincome

Most indicators from Easton Pharmaceutica's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Easton Pharmaceutica current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Easton Pharmaceutica. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in Easton Stock please use our How to Invest in Easton Pharmaceutica guide.The current Selling General Administrative is estimated to decrease to about 161.2 K. The current Discontinued Operations is estimated to decrease to about 966.1 K

	2016	2017	2023	2024 (projected)
Non Recurring	119.2M	113.4M	102.1M	93.4M
Discontinued Operations	10.1M	1.1M	1.0M	966.2K

Non Recurring Discontinued Operations

Easton Pharmaceutica fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Other Liab	Accounts Payable	Short Term Investments	Other Current Assets	Total Liab	Intangible Assets	Common Stock	Property Plant Equipment	Other Current Liab	Total Stockholder Equity	Other Assets	Net Tangible Assets	Retained Earnings	Long Term Debt	Short Long Term Debt	Total Current Assets	Short Term Debt	Net Receivables	Good Will	Other Stockholder Equity	Deferred Long Term Liab	Long Term Investments	Net Debt	Non Current Assets Total
Total Assets		0.33	-0.01	0.71	-0.4	0.73	0.81	-0.51	0.82	-0.77	-0.86	0.94	-0.59	-0.83	-0.46	0.86	-0.66	0.08	0.8	0.86	-0.4	0.87	0.67	-0.93	0.71	0.43
Total Current Liabilities	0.33		0.81	0.67	0.07	-0.16	0.64	-0.45	-0.14	-0.69	-0.58	0.14	-0.31	-0.31	-0.02	0.38	-0.12	-0.36	0.15	0.02	0.07	0.07	0.0	-0.22	0.41	0.46
Other Liab	-0.01	0.81		0.15	-0.03	-0.16	0.21	-0.39	-0.31	-0.55	-0.41	-0.1	-0.11	0.01	0.22	-0.09	0.02	-0.18	-0.09	-0.16	-0.03	-0.14	-0.2	0.06	-0.01	-0.02
Accounts Payable	0.71	0.67	0.15		-0.05	0.1	0.81	-0.45	0.35	-0.6	-0.63	0.53	-0.45	-0.6	-0.38	0.76	-0.34	-0.35	0.49	0.4	-0.05	0.42	0.43	-0.59	0.75	0.73
Short Term Investments	-0.4	0.07	-0.03	-0.05		-0.58	-0.02	0.21	-0.47	0.23	0.34	-0.49	0.33	0.28	-0.31	-0.09	0.28	0.02	-0.46	-0.45	1.0	-0.41	-0.32	0.39	-0.3	0.19
Other Current Assets	0.73	-0.16	-0.16	0.1	-0.58		0.29	-0.41	0.88	-0.53	-0.65	0.85	-0.44	-0.64	-0.34	0.41	-0.56	0.25	0.74	0.86	-0.58	0.82	0.66	-0.79	0.23	-0.17
Total Liab	0.81	0.64	0.21	0.81	-0.02	0.29		-0.52	0.46	-0.68	-0.69	0.58	-0.37	-0.66	-0.42	0.95	-0.33	-0.08	0.57	0.57	-0.02	0.61	0.46	-0.6	0.82	0.77
Intangible Assets	-0.51	-0.45	-0.39	-0.45	0.21	-0.41	-0.52		-0.52	0.66	0.7	-0.44	0.12	0.67	0.47	-0.43	-0.09	0.23	-0.74	-0.65	0.21	-0.64	-0.78	0.43	-0.24	-0.08
Common Stock	0.82	-0.14	-0.31	0.35	-0.47	0.88	0.46	-0.52		-0.49	-0.64	0.87	-0.36	-0.66	-0.54	0.61	-0.51	0.24	0.78	0.91	-0.47	0.87	0.83	-0.81	0.43	0.11
Property Plant Equipment	-0.77	-0.69	-0.55	-0.6	0.23	-0.53	-0.68	0.66	-0.49		0.98	-0.74	0.56	0.72	0.31	-0.53	0.56	0.03	-0.61	-0.61	0.23	-0.64	-0.45	0.78	-0.35	-0.15
Other Current Liab	-0.86	-0.58	-0.41	-0.63	0.34	-0.65	-0.69	0.7	-0.64	0.98		-0.85	0.6	0.8	0.37	-0.59	0.59	0.01	-0.74	-0.74	0.34	-0.75	-0.59	0.87	-0.41	-0.15
Total Stockholder Equity	0.94	0.14	-0.1	0.53	-0.49	0.85	0.58	-0.44	0.87	-0.74	-0.85		-0.63	-0.79	-0.41	0.66	-0.75	0.17	0.78	0.87	-0.49	0.87	0.67	-0.98	0.49	0.15
Other Assets	-0.59	-0.31	-0.11	-0.45	0.33	-0.44	-0.37	0.12	-0.36	0.56	0.6	-0.63		0.46	0.05	-0.34	0.69	-0.28	-0.35	-0.26	0.33	-0.28	-0.27	0.71	-0.39	-0.14
Net Tangible Assets	-0.83	-0.31	0.01	-0.6	0.28	-0.64	-0.66	0.67	-0.66	0.72	0.8	-0.79	0.46		0.49	-0.68	0.28	0.2	-0.95	-0.84	0.28	-0.88	-0.77	0.81	-0.41	-0.18
Retained Earnings	-0.46	-0.02	0.22	-0.38	-0.31	-0.34	-0.42	0.47	-0.54	0.31	0.37	-0.41	0.05	0.49		-0.5	0.14	-0.09	-0.46	-0.53	-0.31	-0.53	-0.53	0.44	-0.25	-0.33
Long Term Debt	0.86	0.38	-0.09	0.76	-0.09	0.41	0.95	-0.43	0.61	-0.53	-0.59	0.66	-0.34	-0.68	-0.5		-0.36	0.0	0.63	0.68	-0.09	0.7	0.55	-0.65	0.86	0.77
Short Long Term Debt	-0.66	-0.12	0.02	-0.34	0.28	-0.56	-0.33	-0.09	-0.51	0.56	0.59	-0.75	0.69	0.28	0.14	-0.36		-0.41	-0.19	-0.39	0.28	-0.38	-0.1	0.77	-0.34	-0.12
Total Current Assets	0.08	-0.36	-0.18	-0.35	0.02	0.25	-0.08	0.23	0.24	0.03	0.01	0.17	-0.28	0.2	-0.09	0.0	-0.41		-0.16	0.03	0.02	0.04	-0.05	-0.14	-0.05	-0.12
Short Term Debt	0.8	0.15	-0.09	0.49	-0.46	0.74	0.57	-0.74	0.78	-0.61	-0.74	0.78	-0.35	-0.95	-0.46	0.63	-0.19	-0.16		0.92	-0.46	0.93	0.88	-0.76	0.4	0.09
Net Receivables	0.86	0.02	-0.16	0.4	-0.45	0.86	0.57	-0.65	0.91	-0.61	-0.74	0.87	-0.26	-0.84	-0.53	0.68	-0.39	0.03	0.92		-0.45	0.99	0.83	-0.81	0.42	0.11
Good Will	-0.4	0.07	-0.03	-0.05	1.0	-0.58	-0.02	0.21	-0.47	0.23	0.34	-0.49	0.33	0.28	-0.31	-0.09	0.28	0.02	-0.46	-0.45		-0.41	-0.32	0.39	-0.3	0.19
Other Stockholder Equity	0.87	0.07	-0.14	0.42	-0.41	0.82	0.61	-0.64	0.87	-0.64	-0.75	0.87	-0.28	-0.88	-0.53	0.7	-0.38	0.04	0.93	0.99	-0.41		0.8	-0.81	0.42	0.13
Deferred Long Term Liab	0.67	0.0	-0.2	0.43	-0.32	0.66	0.46	-0.78	0.83	-0.45	-0.59	0.67	-0.27	-0.77	-0.53	0.55	-0.1	-0.05	0.88	0.83	-0.32	0.8		-0.65	0.31	0.07
Long Term Investments	-0.93	-0.22	0.06	-0.59	0.39	-0.79	-0.6	0.43	-0.81	0.78	0.87	-0.98	0.71	0.81	0.44	-0.65	0.77	-0.14	-0.76	-0.81	0.39	-0.81	-0.65		-0.47	-0.17
Net Debt	0.71	0.41	-0.01	0.75	-0.3	0.23	0.82	-0.24	0.43	-0.35	-0.41	0.49	-0.39	-0.41	-0.25	0.86	-0.34	-0.05	0.4	0.42	-0.3	0.42	0.31	-0.47		0.87
Non Current Assets Total	0.43	0.46	-0.02	0.73	0.19	-0.17	0.77	-0.08	0.11	-0.15	-0.15	0.15	-0.14	-0.18	-0.33	0.77	-0.12	-0.12	0.09	0.11	0.19	0.13	0.07	-0.17	0.87

Click cells to compare fundamentals

Easton Pharmaceutica Account Relationship Matchups

Easton Pharmaceutica fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	2.6M	10.1M	17.2M	10.2M	11.7M	12.3M
Total Current Liabilities	245.8K	792.0K	1.5M	620.8K	558.7K	557.7K
Other Liab	48.3K	46.2K	161.1K	180.2K	162.1K	250.1K
Accounts Payable	30.8K	568.5K	845.1K	255.8K	230.2K	327.4K
Total Liab	2.5M	3.0M	10.1M	3.3M	3.8M	2.0M
Total Stockholder Equity	160.0K	7.1M	7.1M	6.9M	7.9M	8.3M
Other Assets	1.8M	742.6K	95.8K	94.0K	84.6K	80.4K
Net Tangible Assets	(465.0K)	(1.1M)	(1.1M)	(1.0M)	(930.6K)	(884.0K)
Retained Earnings	(39.1M)	(39.2M)	(39.6M)	(39.8M)	(35.8M)	(37.6M)
Long Term Debt	2.2M	2.2M	8.5M	2.5M	2.9M	1.9M
Total Current Assets	198K	66.3K	249.8K	426.3K	383.7K	234.0K
Long Term Investments	926.6M	1.1M	1.7M	1.7M	1.6M	1.5M

Currently Active Assets on Macroaxis

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America
S	SentinelOne
WD	Walker Dunlop

When determining whether Easton Pharmaceutica offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Easton Pharmaceutica's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Easton Pharmaceutica Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Easton Pharmaceutica Stock:

How To Invest In Easton

Details

Is Easton Stock a good investment?

Details

What is Easton Pharmaceutica's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Easton Pharmaceutica. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in Easton Stock please use our How to Invest in Easton Pharmaceutica guide.

You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Easton Pharmaceutica. If investors know Easton will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Easton Pharmaceutica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Revenue Per Share

0.001

Return On Assets

(0.01)

Return On Equity

(0.03)

The market value of Easton Pharmaceutica is measured differently than its book value, which is the value of Easton that is recorded on the company's balance sheet. Investors also form their own opinion of Easton Pharmaceutica's value that differs from its market value or its book value, called intrinsic value, which is Easton Pharmaceutica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Easton Pharmaceutica's market value can be influenced by many factors that don't directly affect Easton Pharmaceutica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Easton Pharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if Easton Pharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Easton Pharmaceutica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Easton Capital Expenditures vs Change To Netincome Analysis

Capital Expenditures vs Change To Netincome

Capital Expenditures vs Change To Netincome Correlation Analysis

Correlation Coefficient

Capital Expenditures

Change To Netincome

Easton Pharmaceutica fundamental ratios Correlations

Easton Pharmaceutica Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Easton Pharmaceutica fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Good Will	+ 1.0	Short Term Investments
Other Stockholder Equity	+ 0.99	Net Receivables
Other Current Liab	+ 0.98	Property Plant Equipment
Long Term Debt	+ 0.95	Total Liab
Total Stockholder Equity	+ 0.94	Total Assets
Other Stockholder Equity	+ 0.93	Short Term Debt

Long Term Investments	- 0.98	Total Stockholder Equity
Short Term Debt	- 0.95	Net Tangible Assets
Long Term Investments	- 0.93	Total Assets
Other Stockholder Equity	- 0.88	Net Tangible Assets
Other Current Liab	- 0.86	Total Assets
Total Stockholder Equity	- 0.85	Other Current Liab